A primate model of schizophrenia using chronic PCP treatment

Reviews in the Neurosciences

Volumn 19, Issue 2-3, 2008, Pages 83-89

  Van Mao, Can ^a,b   Hori, Etsuro ^a,b   Maior, Rafael ^a,b   Ono, Taketoshi ^a,b   Nishijo, Hisao ^a,b  

^a UNIVERSITY OF TOYAMA   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Methamphetamine; Monkey; Negative symptoms; Phencyclidine; Schizophrenia; Social behaviors

Indexed keywords

METHAMPHETAMINE; PHENCYCLIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE MODEL; FEMALE; LONG TERM EXPOSURE; MALE; MONKEY; NEGATIVE SYNDROME; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; SOCIAL BEHAVIOR;

AMPHETAMINE; ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOPAMINE UPTAKE INHIBITORS; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; FEMALE; HALLUCINOGENS; INTERPERSONAL RELATIONS; MACACA FASCICULARIS; MALE; PHENCYCLIDINE; SCHIZOPHRENIA; SOCIAL BEHAVIOR;

EID: 48849111530     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. 3H] flunitrazepam binding in rat brain. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 133-140.
2. Adams B, Moghaddam B. Corticolimbic dopamine neurotransmission is temporally dissociated from cognitive and locomotor effects of phencyclidine. J Neurosci 1998; 18: 5545-5554.
3. Adams BW, Bradberry CW, Moghaddam B. NMDA antagonist effects on striatal dopamine release: microdialysis studies in awake monkeys. Synapse 2002; 43: 12-18.
4. Adler CM, Malhotra AK, Elman I, Goldberg T, Egan M, Pickar D, Breier A. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry 1999; 156: 1646-1649.
5. Balla A, Koneru R, Smiley J, Sershen H, Javitt DC. Continuous phencyclidine treatment induces schizophrenia-like hyperreactivity of striatal dopamine release. Neuropsychopharmacology 2001; 5: 157-164.
6. Balla A, Sershen H, Serra M, Koneru R, Javitt DC. Subchronic continuous phencyclidine administration potentiates amphetamine-induced frontal cortex dopamine release. Neuropharmacology 2003; 28: 34-44.
7. Bell DS. Comparison of amphetamine psychosis and schizophrenia. Br J Psychiatry 1965; 111: 701-707.
8. Carpenter WT, Buchanan RW. Schizophrenia. N Engl J Med 1994; 330: 681-690.
9. Castner SA, Goldman-Rakic PS. Long-lasting psychotomimetic consequences of repeated low-dose amphetamine exposure in Rhesus monkeys. Neuropsychopharmacology 1999; 20: 10-28.
10. Chait LD, Balster RL. Effects of phencyclidine, atropine and physostigmine, alone and in combination, on variable-interval performance in the squirrel monkey. Pharmacol Biochem Behav 1979; 11: 37-42.
11. Cochran SM, Kennedy M, McKerchar CE, Steward LJ, Pratt JA, Morris BJ. Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology 2003; 28: 265-275.
12. Cosgrove KP, Carroll ME. Effect of a no-drug reinforcer, saccharin, on oral self-administration of phencyclidine in male and female rhesus monkeys. Psychopharmacology 2003; 170: 9-16.
13. Ellenbroek BA, Cools AR. Animal models for the negative symptoms of schizophrenia. Behav Pharmacol 2000; 11: 223-233.
14. Frederick DL, Gillam MP, Allen RR, Paule MG. Acute behavioral effects of phencyclidine on rhesus monkey performance in an operant test battery. Pharmacol Biochem Behav 1995; 52: 789-797.
15. Hadland KA, Rushworth MF, Gaffan D, Passingham RE. The effect of cingulate lesions on social behaviour and emotion. Neuropsychologia 2003; 41: 919-931.
16. Javitt DC, Balla A, Burch S, Suckow R, Xie S, Sershen H. Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-D-aspartate receptor/glycinesite agonists. Neuropsychopharmacology 2004; 29: 300-307.
17. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148: 1301-1308.
18. Jentsch JD, Redmond DE, Elsworth JD, Taylor JR, Youngren KD, Roth RH. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 1997; 277: 953-955.
19. Jodo E, Suzuki Y, Takeuchi S, Niwa S, Kayama Y. Different effects of phencyclidine and methamphetamine on firing activity of medial prefrontal cortex neurons in freely moving rats. Brain Res 2003; 962: 226-231.
20. Lee PR, Brady DL, Shapiro RA, Dorsa DM, Koenig JI. Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin. Neuropsychopharmacology 2005; 30: 1883-1894.
21. Linn GS, O'Keeffe RT, Schroeder CE, Lifshitz K, Javitt DC. Behavioral effects of chronic phencyclidine in monkeys. NeuroReport 1999; 10: 2789-2793.
22. Marcotte ER, Pearson DM, Srivastava LK. Animal model of schizophrenia: a critical review. J Psychiatry Neurosci 2001; 26: 395-410.
23. Miczek KA, Yoshimura H. Disruption of primate social behavior by d-amphetamine and cocaine: differential antagonism by antipsychotics. Psychopharmacology 1982; 76: 163-171.
24. Miller MH. Behavioral effects of amphetamine in a group of rhesus monkeys with lesions of dorsolateral frontal cortex. Psychopharmacology 1976; 47: 71-74.
25. Miyamoto Y, Yamada K, Noda Y, Mori H, Mishina M, Nabeshima T. Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor ε1 subunit. J Neurosci 2001; 21: 750-757.
26. Morris BJ, Cochran SM, Pratt JA. PCP: from pharmacology to modeling schizophrenia. Curr Opin Pharmacol 2005; 5: 101-106.
27. Phillips M, Wang C, Johnson KM. Pharmacological characterization of locomotor sensitization induced by chronic phencyclidine administration. J Pharmacol Exp Ther 2001; 296: 905-913.
28. Ridley RM, Baker HF, Owen F, Cross AJ, Crow TJ. Behavioural and biochemical effects of chronic amphetamine treatment in the vervet monkey. Psychopharmacology 1982; 78: 245-251.
29. Sams-Dodd F. Effects of continuous d-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats. Neuropsychopharmacology 1998; 19: 18-25.
30. Scraggs PR, Ridley RM. The effect of dopamine and noradrenaline blockade on amphetamine-induced behaviour in the marmoset. Psychopharmacology 1979; 62: 41-45.
31. Snyder SH. Amphetamine psychosis: a "model" schizophrenia mediated by catecholamines. Am J Psychiatry 1973; 130: 61-67.
32. Tsapakis EM, Travis MJ. Glutamate and psychiatric disorders. Adv Psychiatric Treat 2002; 8: 189-197.